Abstract: Provided is an oligopeptide having preventive and therapeutic effects on infarction diseases. The oligopeptide contains a DE loop sequence of RANKL protein, and has inhibitory activity on proinflammatory cytokine secretion from cells.

Abstract: Methods, devices and systems are described for decreasing the activity of the sympathetic nervous innervation to and from the lungs and the vessels supplying the lungs to treat pulmonary medical conditions such as asthma. In one embodiment, the method may involve advancing an intravascular instrument to a target location in a blood vessel within the intercostal vasculature to ablate either or both the sympathetic afferent and efferent nerves lying within the paravertebral gutter including the visceral fibers that travel to the cardiothoracic cavity and abdominopelvic viscera and the T1 to T4/5 sympathetic chain. In another embodiment, an intravascular instrument may be advanced to the bronchial vessels to ablate either or both the sympathetic afferent and efferent nerves in and around the posterior pulmonary plexus. In one embodiment the ablative agent is a neurolytic agent delivered in a gel. This approach may be utilized to treat other cardiac and pulmonary diseases.

Abstract: Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of a glucagon-like peptide-1 receptor antagonist (GLP1RA) alone or in combination with an amylinomimetic agent or any anti-gastric emptying agent. Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA.

Abstract: Provided are novel skin medical and cosmetic care products as well as compositions for the treatment of the skin based on pulmonary surfactants.

Abstract: Disclosed herein is a method of enhancing the outgrowth of the neurite of a neuron in a subject. The present method comprises administering to the subject a therapeutically effective amount of phosphoglycerate kinase (PGK). Based on the enhancing effect, also disclosed herein is a method of treating a neurological disorder in a subject by use of the PGK or a pharmaceutical composition comprising the PGK and an active agent.

Abstract: The present invention relates to methods of treating or preventing a bacterial disease or infection, antibacterial compositions, and antibacterial surfaces, including isolated endolysin polypeptides from bacteriophage GRCS.

Abstract: The methods and compositions described herein relate to the treatment of bowel inflammation, e.g., IBD or a thrombosis, ischemia, and/or pulmonaryembolism associated with IBD by administering ADAMTS13 to a subject.

Abstract: The present invention relates to a process for preparing a highly pure neurotoxic component of a botulinum toxin by cultivating clostridium botulinum under conditions that allow production of a botulinum toxin, and isolating the neurotoxic component from the botulinum toxin. In addition, the present invention relates to a highly pure neurotoxic component of a botulinum toxin obtainable by the process of the present invention and uses thereof.

Abstract: Disclosed are methods and compositions for treatment of a subject having a biliary disorder. The methods include administering a therapeutically effective amount of a serine protease inhibitor to a subject in need thereof. The biliary disorder include biliary atresia, a biliopathy, Primary Biliary Cirrhosis (PBC), Primary Sclerosing Cholangitis (PSC), and combinations thereof. In certain aspects, the serine protease inhibitor may be a protease inhibitor rC1 Inhibitor.

Abstract: The present invention includes a composition and method for controlling an immune response in a host to a pathogenic bacterial infection comprising: identifying a subject in need of treatment for infection with a pathogenic bacteria; and providing a composition comprising recombinant Cystatin 9 (CST9), a cystatin C (CSTC), or both CST9 and CSTC, in an amount sufficient to restrain or prevent a life-threatening, unrestrained systemic inflammatory response syndrome in a host against a pathogenic bacteria.

Abstract: Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing Leishmaniasis are disclosed.

Abstract: The purpose of the present invention is to provide: a detection agent for specifically detecting a cancer stem cell; a tumor antigen peptide specifically presented by cancer stem cells; a medicinal composition useful in preventing and/or treating cancer, said medicinal composition comprising the aforementioned tumor antigen peptide as an active ingredient; a method for screening the tumor antigen peptide; etc. To achieve the above-mentioned purpose, provided are: peptides represented by YO-XO-ZO; a polyepitope peptide consisting of a plurality of epitope peptides connected together, said polyepitope peptide containing at least one of the above-mentioned peptides as one of the epitope peptides; a polynucleotide encoding the aforementioned peptides and/or polyepitope peptide; a medicinal composition comprising the same as an active ingredient; a prophylactic and/or therapeutic agent for cancer characterized by inducing CTL; etc.

Abstract: The invention provides improved compositions for adoptive cell therapies for cancers that express ROR1.

Abstract: A composition and method for immunizing a mammal infected with Mycobacterium are disclosed. The genes gcpE, pstA, kdpC, papA2, impA, umaA1, fabG2_2, aceAB, mbtH2, lpqP, map0834c, cspB, lipN, or map1634 of M. paratuberculosis and their products that they encode are vaccine targets for Johne's and Crohn's disease. Eighteen M. paratuberculosis-specific genomic islands (MAPs) were identified. Three inverted large genomic fragments in M. paratuberculosis (INV) were also identified. These genomic identifiers represent novel virulence determinants that can be used as targets for vaccines and for developments of drugs against Johne's disease. The method can be used to deliver an immunizing compounds to a mammal, to provide an immune response against Johne's or Crohn's disease in the mammal.

Abstract: Provided herein are methods and compositions for displaying a polypeptide on a tubular structure and uses of such displayed polypeptides in the production of antibodies or vaccines.

Abstract: The present invention relates generally to infectious pancreatic necrosis virus (IPNV) and specifically to further characterisation of the genetic stability of IPNV genome. More in particular, the invention relates to greater appreciation and understanding of the frequency of mutagenesis and codon interactions that influence the replication capabilities, virulence and immunogenicity of the virus. There is provided for the first time a method for developing a commercially applicable IPNV vaccine and a vaccine comprising the IPNV genome carrying particular mutations and codons. There are also described uses in prophylaxis or treatment of infectious pancreatic necrosis (IPN) disease.

Abstract: The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones.

Abstract: This disclosure provides attenuated swine influenza strains, particularly those produced via a reverse genetics approach, compositions comprising same, and methods of production and use thereof.

Abstract: The present specification discloses recombinant nucleic acid constructs encoding an immunogenic multiepitope polypeptide comprising two or more polypeptides, recombinant nucleic acid constructs encoding at least two epitopes from two or more internal proteins of influenza virus, compositions comprising such recombinant nucleic acid constructs and methods of eliciting a T cell immune response against an influenza virus in a vertebrate using such recombinant nucleic acid constructs and compositions.

Abstract: The present invention relates to a porcine parvovirus and porcine reproductive and respiratory syndrome virus vaccine for protecting a subject, preferably swine, against diseases associated with porcine parvovirus and porcine reproductive and respiratory syndrome virus. The present invention further relates to methods of producing immunogenic compositions as well as such immunogenic compositions exhibiting reduced virucidal activity.

Abstract: The present invention features methods of treating lung cancer (e.g., NSCLC) with an anti-PD-L1 antibody and a tyrosine kinase inhibitor in a subject identified as having an EGFR mutation-positive tumor.

Abstract: A method of averting opioid addiction in a patient is disclosed. The method can be applied to a patient suffering from moderate to severe low back pain (LBP). The method comprises: diagnosing the patient as suffering from low back; administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of an antibody that binds specifically to nerve growth factor (NGF) or an antigen binding fragment thereof; and avoiding administration of an opioid to the patient, and thereby relieving pain, and averting opioid addiction in a patient.

Abstract: To provide a superior anti-human NGF antibody Fab fragment that maintains a high neutralizing activity, and that reduces systemic side-effects arising from systemic exposure while expressing a local drug effect, and means for treating postoperative pain by using such antibody fragment. An anti-human NGF antibody Fab fragment comprising a heavy-chain fragment consisting of the amino acid sequence shown by SEQ ID NO:5 and a light-chain consisting of the amino acid sequence shown by SEQ ID NO: 8.

Abstract: Provided is an irinotecan-loaded dual-reverse thermosensitive formulation, which is a dual-reverse thermosensitive hydrogel composition including nanoparticles including irinotecan and lipids; a hydrogel; and a stabilizer.

Abstract: The present invention relates to an ophthalmic composition in the form of an oil-in-water emulsion comprising a mucomimetic polymer and lipoic acid as emulsion stabilizer. It also relates to a process for stabilizing emulsions with lipoic acid and to the use of this acid for stabilizing the oil-in-water emulsions comprising a mucomimetic polymer.

Abstract: The invention provides an amorphous metal-organic framework for use in methods of treatment. The amorphous metal-organic framework may hold a component for delivery. The amorphous metal-organic framework is obtained or is obtainable by amorphization of a crystalline amorphous metal-organic framework holding the component. The amorphous metal-organic framework may be a zirconium-containing or a bismuth-containing metal-organic framework, such as a framework having arylcarboxylate ligands, such as benzenedicarboxylate ligands.

Abstract: Compositions useful in the treatment of cough and cold symptoms, including but not limited to, cough, nasal congestion and sore throat, are disclosed.

Abstract: Aspects of the present disclosure generally relate to compounds for targeting and healing bone fractures. Some of these compounds include a negatively charged oligopeptide comprising an acidic oligopeptide, a linker, which may be hydrolyzable or may be a substrate for the protease cathepsin K, and at least one molecule that promotes bone healing. In some compounds the molecule that promotes bone healing is an anabolic compound that inhibits GSK3?, in some compounds the molecule that promotes the healing of bone fracture is a pro-inflammatory agent such as PGE1. Other embodiments include methods of treating a bone fracture comprising administering a therapeutic amount of any one of the compounds disclosed herein.

Abstract: Embodiments of the disclosure pertain to compositions containing (i) one or more non-antifreeze proteins or cell components or cells and (ii) one or more antifreeze proteins (AFPs), mimetics thereof, and/or analogs thereof, and a method of stabilizing a biologic (e.g., a protein, microbe, cell component or cell) against temperature stress and aggregation. The AFP may be selected from known antifreeze polypeptides and antifreeze peptides, analogs and mimetics of antifreeze proteins, active fragments of such antifreeze proteins, polypeptide and peptide mimetics, antifreeze peptoids and polymers, and combinations thereof. The non-antifreeze protein, cell component or cell comprises a known protein, cell component or cell used in the pharmaceutical, medical, agricultural, veterinary and/or food industry(ies). The AFP protects the function of the non-antifreeze protein, microbe(s), cell component(s) or cell(s) under temperature stress (e.g., a temperature of ?20-60° C.).

Abstract: Pharmaceutical compositions are provided for extending the serum half-life of a therapeutic agent. The composition may include a strained alkyne-labeled therapeutic agent. Also provided is a strained alkyne-carrier protein adduct including a vinyl thioether-linkage to a cysteine residue of the carrier protein. Methods of chemoselectively modifying a carrier protein are provided, that include conjugating a cysteine residue of a carrier protein with a cyclooctyne-labeled cargo agent to produce a vinyl thioether-linked conjugate. Also provided is a method of increasing the in vivo half-life of a bioactive agent including administering a strained alkyne-labeled bioactive agent to a subject.

Abstract: This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.

Abstract: The invention provides a combination of an antibacterial agent (in particular vancomycin or moenomycin) and a delivery agent, in which the delivery agent is bonded, or capable of binding, to the antibacterial agent, and in which the delivery agent is capable of binding to one or more structures on a bacterial cell membrane. The invention further provides the use of such combinations in treating or preventing bacterial infections.

Abstract: This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors.

Abstract: A method for producing an antibody-drug conjugate composition, comprising: (i) a step of reacting an antibody with a reducing agent in a buffer to reduce interchain disulfides, and (ii) a step of reacting drug linker intermediates with the antibody having thiol groups obtained in the step (i), wherein the reaction temperature in the step (i) is ?10° C. to 10° C., and the average number of bound drugs in the produced antibody-drug conjugate composition is 3.5 to 4.5, and the content of antibody-drug conjugates in which four drug linkers are bound to heavy-light interchain thiols, in the produced antibody-drug conjugate composition is 50% or more; and an antibody-drug conjugate composition, wherein the content of antibody-drug conjugates wherein the average number of bound drugs is 3.5 to 4.5, and the content of antibody-drug conjugates in which four drug linkers are bound to heavy-light interchain thiols, is 50% or more.

Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

Abstract: Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.

Abstract: A type of trimaleimide linkers and uses thereof are disclosed. The trimaleimide linkers can be applied for preparation of antibody-drug conjugate as shown by formula I: L-(T-A-D)nI wherein, L is an antibody, antibody fragment or protein; T is a trimaleimide linker; A is a cleavable linker group or a noncleavable linker; D is a drug; n is an integer ranging from 1 to 8.

Abstract: The present disclosure is directed to carbon nanomaterials and methods for delivering a drug to a mammal's cell including administering the carbon nanomaterial to the mammal. The present disclosure is also directed to carbon nanomaterials and methods for delivering a nucleic acid to a mammal's cell including administering the carbon nanomaterial to the mammal.

Abstract: The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug/cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 ?m.

Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

Abstract: The present invention relates to a replication retrovirus vector system comprising thymidine kinase (HSV-TK) gene and cytosine deaminase (CD) gene which make gene transfer to cancer cell tissue for the efficient treatment of cancer. Particularly, the HSV-TK/CD combined self-replicating retrovirus vector system of the present invention characteristically contains both HSV-TK and CD genes; has no worries about losing a therapeutic gene because recombination does not occur in this system during virus infection; and has an excellent stability, and also is able to induce cancer cell death by using the prodrug GCV or 5-FC and can apply a therapeutic gene or a prodrug thereof selectively to such cancer that shows resistance against cancer treatment using either TK or CD, so that this system of the invention can be advantageously used as a pharmaceutical composition for the treatment of cancer.

Abstract: The present invention is directed, in part, to the treatment of a subject having a neurodegenerative disorder, such as Parkinson's disease (PD), by providing glucocerebrosidase enzyme. The enzyme may be provided, e.g., through gene therapy or by administration of a glucocerebrosidase protein. Accordingly, the present invention encompasses glucocerebrosidase nucleic acids or proteins for use in the treatment of PD or other neurodegenerative disorders.

Abstract: The present invention relates to methods for improving the detection of pathologies in the colon and method of flagging the mucosal lesions in the colon.

Abstract: Methods of measurement of biometric indicators in a mammalian subject are described. Biometric indicators of interest include hematocrit, plasma volume, volume of distribution, and glomerular filtration rate. The methods are especially applicable to subjects with rapid blood loss and to subjects with unstable hematocrits. Hematocrit may be measured by administering an injectate with a dynamic fluorescent marker and a static fluorescent marker, or a single static marker with two fluorescent tags, into the vascular system of the subject, and monitoring the emission intensities of the markers or fluorescent tags over a period of time. Hematocrit may then be calculated using a calibrated spectrometric analyzer by determining the raw ratio of the markers at T0, calculating the apparent hematocrit, and applying a correction factor.

Abstract: A fluorescent tracer for targeting tumors, comprises: at least one first fluorophore fluorescing in a range of wavelengths of between 700 and 1000 nm, a targeting assembly comprising at least two identical targeting molecules, and a cyclic oligopeptide: configured so as to define a mean plane defining a first upper face and a second lower face, comprising at least one first lysine amino acid residue on the second lower face, the targeting molecules being fixed to the first upper face of the mean plane, the fluorophore being fixed to the second lower face of the mean plane via a spacer arm connecting a carbon of the sequence of the at least three double bonds and the lysine amino acid residue of the oligopeptide.

Abstract: The present invention relates to a method of in vivo imaging with meta-[123I]iodobenzylguanidine ([123I]mIBG) and more particularly wherein said method is used to stratify a defined subset of subjects with heart failure into particular treatment regimens.

Abstract: The present invention relates to a method of in vivo imaging with meta-[123I]iodobenzylguanidine ([123I]mIBG) and more particularly wherein said method is used to stratify a defined subset of subjects with heart failure into particular treatment regimens.

Abstract: A method and system for treating a biological fluid within a container by subjecting the container to light is provided. The system includes a fluid treatment chamber for receiving the container of biological fluid; an agitation assembly for oscillating the container of biological fluid within the fluid treatment chamber including a variable speed motor; one or more light sources in proximity to the fluid treatment chamber; at least one sensor for sensing a condition of the biological fluid in the container; and a programmable controller.

Abstract: Method for sterilizing a hydrogel composition include subjecting the composition to pulsed light comprising broadband spectrum radiation, the pulsed light being at a dose effective to sterilize the composition without causing significant change in rheology of the composition.

Abstract: A sterilizing sheet is excellent in terms of saving space when a sterilizing operation is being performed, and sterilizing objects of various sizes. This sterilizing sheet is provided with a flexible sheet body, a sheet accommodating body and a handle. The sheet body is formed from a dielectric and a pair of electrodes accommodated inside the dielectric. The sheet accommodating body is a cylindrical body in which the sheet body is accommodated to be capable of being pulled out and rewound, and is provided with a case, a rotating body and a rewinding mechanism. The rewinding mechanism is a mechanism for automatically rewinding the sheet body, when pulled out from the sheet accommodating body, back into the sheet accommodating body. The handle is attached to a distal end portion of the sheet body, and includes, inside the handle, a battery, a switch mechanism, a booster circuit and a monitoring circuit.